Acumen Pharmaceuticals (ABOS) Q2 2024 earnings summary

Executive summary

• Sabirnetug, a next-generation monoclonal antibody targeting amyloid beta oligomers for early Alzheimer's disease, is advancing with Phase 2 ALTITUDE-AD and subcutaneous studies, showing strong clinical execution and positive Phase 1 results.

• Enrollment in the ALTITUDE-AD Phase 2 trial is ahead of expectations, with over 50 sites across North America, UK, and EU, and the first subject dosed in May 2024.

• Subcutaneous formulation development is progressing via a partnership with Halozyme, with a Phase 1 PK study initiated in July 2024 and topline results expected in Q1 2025.

• New biomarker and patient experience data presented at AAIC 2024 reinforce sabirnetug’s mechanism and patient-centric trial design.

• Acumen holds exclusive global rights to sabirnetug, with strong IP protection and market exclusivity into the 2030s.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $281.4 million as of June 30, 2024, supporting operations into the first half of 2027.

• R&D expenses were $19.5 million for Q2 2024, up year-over-year due to increased clinical trial activity.

• G&A expenses reached $4.8 million for Q2 2024, reflecting higher personnel costs.

• Net loss for Q2 2024 was $20.5 million, up from $11.6 million in Q2 2023.

• Net cash used in operating activities was $34.4 million for the six months ended June 30, 2024.

Outlook and guidance

• Cash runway is expected to last into the first half of 2027, supporting ongoing and planned clinical development.

• Topline results from the Phase 1 subcutaneous sabirnetug study are anticipated in Q1 2025.

• ALTITUDE-AD Phase 2 trial enrollment is expected to complete in the first half of 2025.

• Virtual R&D Day is planned for October 2, 2024, to provide updates on clinical development.

• Expenses and operating losses are projected to increase as clinical development progresses.